Takeda have agreed to divest a number of over the counter and prescription medicines in emerging markets to Acino.
The markets are all within Takeda’s Growth and Emerging Markets Business Unit, and include Near East, Middle East and Africa countries. Acino, will acquire the rights, title and interest to the products in the agreed portfolio, exclusively for the selected countries.
“Takeda divests OTC and prescription medicines to Acino for $200m“
Ricardo Marek, President, Growth and Emerging Markets Business Unit for Takeda said “As we continue to work on our life changing portfolio of innovative products, we still remain committed to this region, via our commercial activities and our access to medicines programme. We are confident that Acino is best positioned to provide uninterrupted access and supply of the divested products to patients.”
The deal is set to close by the fourth quarter of 2019, subject to the satisfaction of closing conditions from Takeda. They plan to use the cash from the deal to reduce their debts following the takeover of Shire.